Published in Obesity and Diabetes Week, October 17th, 2005
"In the last year, we achieved key clinical and company milestones with the approval of clinical trials for our lead products and the completion of a major licensing agreement for our regenerative diabetes program", said Dr. Tony Cruz, chairman and CEO of Transition.
During the fiscal year, Transition's lead regenerative diabetes product, E1-I.N.T., received clearance from the U.S. Food and Drug Administration (FDA) to commence exploratory Phase 2a clinical trials in both type 1 and type 2 diabetes....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.